Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 25

Sort by

Sort Order Select

Journal Articles

The association of a novel psychosocial and mobility assessment with outcomes of veterans with acute myeloid leukemia (AML)

Michelle Lee, Nhan Do, Mary Brophy, Amir Fathi, Areej El-Jawahri, Gabriela Hobbs, Elyse Park, Nathanael Fillmore, Clark DuMontier, Jennifer La

Blood (2025) 146 (Supplement 1): 2836.

https://doi.org/10.1182/blood-2025-2836

Published: 2025

Journal Articles

Engineering dual-specificity PPM1D inhibitors to enhance therapeutic response and overcome chemoresistance in TP53-mutant malignancies

Peter Miller, Ygang Tang, David McKinney, Mikolaj Slabicki, Rishi Puram, Adam Sperling, Michelle Lee, Jennifer Roth, Alexandra Gould, Eugene Oh

Blood (2025) 146 (Supplement 1): 5048.

https://doi.org/10.1182/blood-2025-5048

Published: 2025

Journal Articles

Decreased serum total cholesterol is associated with worse outcomes among patients with myeloproliferative neoplasms

Orly Leiva, Steven Soo, Olivia Liu, Victor You, Andrew Palmer, Justin Kahla, Yasmeen Murtaza, Olatoyosi Odenike, Anand Patel, Jeanne DeCara, Michelle Lee, Chi-Joan How, Max Petersen, Patrycja Dubielecka, Gabriela Hobbs

Blood (2025) 146 (Supplement 1): 2020.

https://doi.org/10.1182/blood-2025-2020

Published: 2025

Journal Articles

Can we perform allogeneic hematopoietic cell transplantation (HCT) safely in patients with limited social supports and substantial psychosocial complexity?

Nicolas Trad, Matthew Reynolds, Maya Abdallah, John Mark Sloan, Richard Newcomb, Jennifer D'Alotto, Julie Vanderklish, Nived Subhendu, Michelle Lee, Zachariah Defilipp, Thomas Spitzer, Yi-Bin Chen, Areej El-Jawahri

Blood (2025) 146 (Supplement 1): 4617.

https://doi.org/10.1182/blood-2025-4617

Published: 2025

Journal Articles

Retrospective real-world analysis of ropeginterferon ALFA-2B use in patients with polycythemia vera and essential thrombocythemia: Practice patterns, tolerance, and outcomes

Katherine Feder, Jessica Freydman, Yue Ren, Shruti Gajjar, Victor You, David Sirignano, Svitlana Tyekucheva, Andrew Brunner, Jean M. Connors, Daniel Deangelo, Amir Fathi, Jacqueline Garcia, Chi-Joan How, Marlise Luskin, Richard Stone, Virginia Volpe, Michelle Lee, Gabriela Hobbs

Blood (2025) 146 (Supplement 1): 7338.

https://doi.org/10.1182/blood-2025-7338

Published: 2025

Journal Articles

Ruxolitinib and cardiovascular outcomes among patients with myelofibrosis

Orly Leiva, Steven Soo, Olivia Liu, Victor You, Andrew Palmer, Justin Kahla, Yasmeen Murtaza, Olatoyosi Odenike, Anand Patel, Jeanne DeCara, Michelle Lee, Chi-Joan How, Gabriela Hobbs

Blood (2025) 146 (Supplement 1): 3796.

https://doi.org/10.1182/blood-2025-3796

Published: 2025

Journal Articles

Results from paradigm - a phase 2 randomized multi-center study comparing azacitidine and venetoclax to conventional induction chemotherapy for newly diagnosed fit adults with acute myeloid leukemia

Blood (2025) 146 (Supplement 1): 6.

https://doi.org/10.1182/blood-2025-6

Published: 2025

Journal Articles

Sasp-driven immune evasion defines a novel African ancestry-associated DLBCL subtype with distinctive molecular and immune vulnerabilities

Blood (2025) 146 (Supplement 1): 3.

https://doi.org/10.1182/blood-2025-3

Published: 2025

Journal Articles

Real-world practice patterns of IDH inhibitors and outcomes of on-label IDH inhibitor use for Acute Myeloid Leukemia in the United States

Blood (2025) 146 (Supplement 1): 1614.

https://doi.org/10.1182/blood-2025-1614

Published: 2025

Journal Articles

Real-world outcomes of myelodysplastic syndrome and chronic myelomonocytic leukemia treated with IDH1 and IDH2 inhibitors in the frontline setting

Alifya Lokhandwala, Cilomar Martins de Oliveira Filho, Philip Amrein, Amir Fathi, Gabriela Hobbs, Hanno Hock, Rupa Narayan, Andrew Brunner, Michelle Lee

Blood (2025) 146 (Supplement 1): 8171.

https://doi.org/10.1182/blood-2025-8171

Published: 2025

Journal Articles

Evaluating real-world diagnostic and treatment patterns, risk of thromboembolic events, and mortality for polycythemia vera across an integrated academic-community cancer network

Jessica Nino De Rivera, Orly Leiva, Vasileios Efthymiou, Odette Iskandar, Jessica Freydman, Gabriela Hobbs, Michelle Lee

Blood (2025) 146 (Supplement 1): 6390.

https://doi.org/10.1182/blood-2025-6390

Published: 2025

Journal Articles

Pulmonary hypertension on right heart catheterization is associated with worse progression-free survival in patients with myeloproliferative neoplasms

Orly Leiva, Olivia Liu, Victor You, Steven Soo, Justin Kahla, Yasmeen Murtaza, Andrew Palmer, Anand Patel, Olatoyosi Odenike, Michelle Lee, Chi-Joan How, Gabriela Hobbs

Blood (2025) 146 (Supplement 1): 5583.

https://doi.org/10.1182/blood-2025-5583

Published: 2025

Journal Articles

Impact of statin use on cardiovascular and hematologic outcomes among patients with myeloproliferative neoplasms

Orly Leiva, Steven Soo, Olivia Liu, Victor You, Andrew Palmer, Justin Kahla, Yasmeen Murtaza, Olatoyosi Odenike, Anand Patel, Jeanne DeCara, Max Petersen, Patrycja Dubielecka, Michelle Lee, Chi-Joan How, Gabriela Hobbs

Blood (2025) 146 (Supplement 1): 5571.

https://doi.org/10.1182/blood-2025-5571

Published: 2025

Journal Articles

Safety and efficacy of rilzabrutinib vs placebo in adults with immune thrombocytopenia: the phase 3 LUNA3 study

Blood (2025) 145 (24): 2914–2926.

https://doi.org/10.1182/blood.2024027336

Published: 2025

Includes: Supplemental data

Journal Articles

Gamma Secretase Inhibition May Mitigate the Impact of Low BCMA Target Density in Relapsed/Refractory Multiple Myeloma: Results from a Comparative Analysis of Two Phase 1 Clinical Trials

Blood (2024) 144 (Supplement 1): 4832.

https://doi.org/10.1182/blood-2024-205942

Published: 2024

Journal Articles

Bruton Tyrosine Kinase Inhibitor Rilzabrutinib Reduces Vaso-Occlusion and Markers of Inflammation and Adhesion in Transgenic Mice with Sickle Cell Disease

Ahmed Daak, David R. Light, Fuad Abdulla, Chunsheng Chen, Julia Nguyen, Conglin Ruan, Michael Storek, Dimitry Ofengeim, Alexandra Hicks, Michelle Lee, Vincent Mikol, Gregory M. Vercellotti, John D. Belcher

Blood (2024) 144 (Supplement 1): 2482.

https://doi.org/10.1182/blood-2024-200182

Published: 2024

Journal Articles

Sutimlimab Provides Sustained Improvements in Patient-Reported Outcomes and Quality of Life in Patients with Cold Agglutinin Disease: Open-Label Extension of the Randomized, Phase 3 Cadenza Study

Alexander Roeth, Catherine M. Broome, Wilma Barcellini, Bernd Jilma, Quentin A. Hill, David Cella, Tor Henrik Anderson Tvedt, Masaki Yamaguchi, Irina Murakhovskaya, Michelle Lee, Frank Shafer, Marek Wardecki, Jennifer Wang, Ronnie Yoo, Jerome Mshijid, Ilene C. Weitz

Blood (2022) 140 (Supplement 1): 70–72.

https://doi.org/10.1182/blood-2022-159966

Published: 2022

Journal Articles

Sustained Complement C1s Inhibition with Sutimlimab in Patients with Cold Agglutinin Disease Results in Continued Efficacy during Part B of the Randomized Placebo-Controlled Phase 3 Cadenza Study (NCT03347422)

Blood (2022) 140 (Supplement 1): 2825–2827.

https://doi.org/10.1182/blood-2022-159562

Published: 2022

Journal Articles

Sutimlimab in patients with cold agglutinin disease: results of the randomized placebo-controlled phase 3 CADENZA trial

Alexander Röth, Sigbjørn Berentsen, Wilma Barcellini, Shirley D’Sa, Bernd Jilma, Marc Michel, Ilene C. Weitz, Masaki Yamaguchi, Jun-ichi Nishimura, Josephine M. I. Vos, Michael Storek, Nancy Wong, Parija Patel, Xiaoyu Jiang, Deepthi S. Vagge, Marek Wardęcki, Frank Shafer, Michelle Lee, Catherine M. Broome

Blood (2022) 140 (9): 980–991.

https://doi.org/10.1182/blood.2021014955

Published: 2022

Includes: Supplemental data

Journal Articles

Inhibition of Complement C1s By Sutimlimab in Patients with Cold Agglutinin Disease (CAD): Efficacy and Safety Results from the Randomized, Placebo-Controlled Phase 3 CADENZA Study

Blood (2021) 138 (Supplement 1): 349.

https://doi.org/10.1182/blood-2021-148066

Published: 2021

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

The association of a novel psychosocial and mobility assessment with outcomes of veterans with acute myeloid leukemia (AML)

Engineering dual-specificity PPM1D inhibitors to enhance therapeutic response and overcome chemoresistance in TP53-mutant malignancies

Decreased serum total cholesterol is associated with worse outcomes among patients with myeloproliferative neoplasms

Can we perform allogeneic hematopoietic cell transplantation (HCT) safely in patients with limited social supports and substantial psychosocial complexity?

Retrospective real-world analysis of ropeginterferon ALFA-2B use in patients with polycythemia vera and essential thrombocythemia: Practice patterns, tolerance, and outcomes

Ruxolitinib and cardiovascular outcomes among patients with myelofibrosis

Results from paradigm - a phase 2 randomized multi-center study comparing azacitidine and venetoclax to conventional induction chemotherapy for newly diagnosed fit adults with acute myeloid leukemia

Sasp-driven immune evasion defines a novel African ancestry-associated DLBCL subtype with distinctive molecular and immune vulnerabilities

Real-world practice patterns of IDH inhibitors and outcomes of on-label IDH inhibitor use for Acute Myeloid Leukemia in the United States

Real-world outcomes of myelodysplastic syndrome and chronic myelomonocytic leukemia treated with IDH1 and IDH2 inhibitors in the frontline setting

Evaluating real-world diagnostic and treatment patterns, risk of thromboembolic events, and mortality for polycythemia vera across an integrated academic-community cancer network

Pulmonary hypertension on right heart catheterization is associated with worse progression-free survival in patients with myeloproliferative neoplasms

Impact of statin use on cardiovascular and hematologic outcomes among patients with myeloproliferative neoplasms

Safety and efficacy of rilzabrutinib vs placebo in adults with immune thrombocytopenia: the phase 3 LUNA3 study

Gamma Secretase Inhibition May Mitigate the Impact of Low BCMA Target Density in Relapsed/Refractory Multiple Myeloma: Results from a Comparative Analysis of Two Phase 1 Clinical Trials

Bruton Tyrosine Kinase Inhibitor Rilzabrutinib Reduces Vaso-Occlusion and Markers of Inflammation and Adhesion in Transgenic Mice with Sickle Cell Disease

Sutimlimab Provides Sustained Improvements in Patient-Reported Outcomes and Quality of Life in Patients with Cold Agglutinin Disease: Open-Label Extension of the Randomized, Phase 3 Cadenza Study

Sustained Complement C1s Inhibition with Sutimlimab in Patients with Cold Agglutinin Disease Results in Continued Efficacy during Part B of the Randomized Placebo-Controlled Phase 3 Cadenza Study (NCT03347422)

Sutimlimab in patients with cold agglutinin disease: results of the randomized placebo-controlled phase 3 CADENZA trial

Inhibition of Complement C1s By Sutimlimab in Patients with Cold Agglutinin Disease (CAD): Efficacy and Safety Results from the Randomized, Placebo-Controlled Phase 3 CADENZA Study

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only